Inhibikase Therapeutics (IKT) Net Cash Flow Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 53.46% |
| 10 | Inhibikase Therapeutics | 401.48 Mn | 231.11 Mn | - | -628.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -628.86% |
| Dec 31, 2025 | 81.64% |
| Sep 30, 2025 | -1,716.49% |
| Jun 30, 2025 | 486.72% |
| Mar 31, 2025 | 348.84% |
| Dec 31, 2024 | 1,075.70% |
| Sep 30, 2024 | -116.77% |
| Jun 30, 2024 | 135.74% |
| Mar 31, 2024 | -110.77% |
| Dec 31, 2023 | -504.95% |
| Sep 30, 2023 | 149.02% |
| Jun 30, 2023 | 53.36% |
| Mar 31, 2023 | 21.91% |
| Dec 31, 2022 | 134.34% |
| Sep 30, 2022 | -1,227.75% |
| Jun 30, 2022 | -111.82% |
| Mar 31, 2022 | 4.72% |
| Dec 31, 2021 | -129.39% |
| Sep 30, 2021 | -23,845.75% |
| Jun 30, 2021 | 694,632.18% |